Iterum
Jan 28, 2021
Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials
Nirogy Therapeutics rises with USD 16.5 Million to target metabolite transporters Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules for targeting cellular transporters, announced the closing of a USD 16.5 million Series A financing. Nirogy plans to use the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
